Black Diamond Therapeutics, Inc. balance sheet BDTX

Annual Quarterly

As of Jun 30, 2026, Black Diamond Therapeutics, Inc. had total assets of $125.0 million and total liabilities of $28.9 million. Total assets were down 24.9% from a year earlier. Stockholders' equity was $96.1 million. It held $110.5 million in cash and investments against $17.0 million of total debt, net cash of $93.5 million. The current ratio, current assets divided by current liabilities, was 7.28.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
Assets
Cash
19
-36.0%
21
-42.4%
36
-35.2%
56
+63.8%
34
-47.8%
66
+90.1%
35
-77.6%
155
Short-term investments
91
-19.1%
108
+73.3%
62
-17.3%
75
-15.0%
88
-38.5%
144
-48.7%
280
—
Cash and investments
111
-22.6%
129
+30.5%
99
-25.0%
131
+7.0%
123
-41.5%
210
-33.4%
315
+103.7%
155
Total current assets
115
-21.4%
132
+30.9%
101
-24.5%
134
+5.0%
128
-40.8%
216
-32.5%
320
+105.2%
156
Property and equipment, net
0
-74.5%
0
-73.7%
1
-19.8%
2
-33.1%
3
-14.8%
3
+688.3%
0
+134.8%
0
Total assets
125
-24.9%
143
+16.6%
123
-22.7%
159
+1.5%
156
-36.9%
248
-24.9%
330
+108.3%
158
Liabilities and equity
Accounts payable
1
+82.1%
1
-85.6%
4
+72.4%
2
+23.8%
2
-54.3%
4
+61.8%
3
+29.2%
2
Total current liabilities
16
-5.7%
16
-23.5%
21
+4.7%
20
+28.7%
15
-35.4%
24
+66.3%
14
+192.4%
5
Total liabilities
29
-14.3%
31
-21.7%
39
-5.9%
42
+3.1%
41
-21.7%
52
+136.3%
22
+349.1%
5
Stockholders' equity
96
-27.5%
112
+34.7%
83
-28.7%
117
+0.9%
116
-40.9%
196
-36.3%
308
+752.6%
-47
Debt
Lease liabilities
17
-18.2%
19
-15.3%
22
-12.3%
25
-10.1%
28
-4.5%
29
+237.1%
9
—
Total debt
17
-18.2%
19
-15.3%
22
-12.3%
25
-10.1%
28
-4.5%
29
+237.1%
9
—
Net cash
94
-23.4%
110
+43.8%
76
-28.0%
106
+12.1%
95
-47.5%
180
-41.1%
306
—
Ratios
Current ratio
7.28x
8.42x
4.92x
6.82x
8.37x
9.12x
22.48x
32.02x
Debt to equity
0.18x
0.17x
0.27x
0.22x
0.24x
0.15x
0.03x
—
Debt to EBITDA
—
1.46x
—
—
—
—
—
—
Return on equity
-44.29%
19.93%
-83.66%
-70.62%
-78.80%
-64.11%
-21.85%
—
Return on assets
-34.04%
15.64%
-56.81%
-51.99%
-58.35%
-50.71%
-20.40%
-22.27%
Book value per share
1.67
1.96
1.47
2.26
3.18
5.41
8.53
-21.08
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BDTX (Nasdaq)
Fiscal year ends
December 31
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1701541
Former names
Aset Therapeutics, Inc. (until Jan 4, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.